FDA Clearance Tracker · P160054-S019
HeartMate 3 Left Ventricular Assist System (LVAS)
Last checked: Nov 20, 2026Latest source record: Aug 12, 2019 (this decision)Source: openFDAMethods & limitations
Decided
Aug 12, 2019
Approved
Time to decision
54 days
Received Jun 19, 2019. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P160054-S019
- Device name
- HeartMate 3 Left Ventricular Assist System (LVAS)
- Applicant
- ABBOTT MEDICAL
- Applicant location
- Pleasanton, CA
- Received
- Jun 19, 2019
- Decided
- Aug 12, 2019
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P160054
Device type
- Device type
- Ventricular (assist) bypass (DSQ)
- Device class
- Class III
- Specialty
- Cardiology
FDA's approval statement
As written in FDA's record.
Approval for a manufacturing site located at Sterigenics in Salt Lake City, Utah for ethylene oxide sterilization of the HeartMate 3 LVAS and HeartMate II LVAS components.
Source documents
Other decisions for ABBOTT MEDICAL
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P260019 · Decided Oct 27, 2026 · 180 days after receipt
Device type: Para-device leak occluder (SJT) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.